Literature DB >> 15175907

T-cell-mediated lysis of B cells induced by a CD19xCD3 bispecific single-chain antibody is perforin dependent and death receptor independent.

Michael Gruen1, Kurt Bommert, Ralf C Bargou.   

Abstract

A recently developed bispecific antibody construct, directed against CD19 and CD3 (bscCD19xCD3), induces T-cell-mediated lysis of allogeneic and autologous B cells in a specific and highly efficient manner. Since knowledge of the molecular mechanisms underlying this lysis is limited, a study on bscCD19xCD3-activated T-cell-effector pathways was performed. BscCD19xCD3-induced lysis of target B-cell lines Nalm-6, Daudi, and Raji and of autologous primary B cells is caused by the perforin-dependent granule-exocytosis pathway but not by the death ligands FasL, TRAIL, or TNF-alpha. When activated by bscCD19xCD3 and Raji cells, T cells express FasL mRNA, but incubation of Raji cells with cell-free supernatants from cytotoxicity experiments caused an upregulation of c-Flipl, possibly accounting for the cells' insensitivity toward death-receptor-mediated lysis. In addition to granule exocytosis, Raji cells are lysed by at least one mechanism independent of perforin, which requires transport through the T cell's Golgi apparatus. Copyright 2004 Springer-Verlag

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15175907     DOI: 10.1007/s00262-003-0496-2

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  13 in total

Review 1.  Are BiTEs the "missing link" in cancer therapy?

Authors:  Carter M Suryadevara; Patrick C Gedeon; Luis Sanchez-Perez; Terence Verla; Christopher Alvarez-Breckenridge; Bryan D Choi; Peter E Fecci; John H Sampson
Journal:  Oncoimmunology       Date:  2015-04-30       Impact factor: 8.110

2.  A novel synthetic naïve human antibody library allows the isolation of antibodies against a new epitope of oncofetal fibronectin.

Authors:  Alessandra Villa; Valeria Lovato; Emil Bujak; Sarah Wulhfard; Nadine Pasche; Dario Neri
Journal:  MAbs       Date:  2011-05-01       Impact factor: 5.857

Review 3.  The role of blinatumomab in patients with relapsed/refractory acute lymphoblastic leukemia.

Authors:  Jonathan E Benjamin; Anthony S Stein
Journal:  Ther Adv Hematol       Date:  2016-04-04

Review 4.  Advances in targeted therapy for malignant lymphoma.

Authors:  Li Wang; Wei Qin; Yu-Jia Huo; Xiao Li; Qing Shi; John E J Rasko; Anne Janin; Wei-Li Zhao
Journal:  Signal Transduct Target Ther       Date:  2020-03-06

Review 5.  Blinatumomab: enlisting serial killer T-cells in the war against hematologic malignancies.

Authors:  Britny Rogala; Craig W Freyer; Evelena P Ontiveros; Elizabeth A Griffiths; Eunice S Wang; Meir Wetzler
Journal:  Expert Opin Biol Ther       Date:  2015-06       Impact factor: 4.388

Review 6.  Redirecting T cells to eradicate B-cell acute lymphoblastic leukemia: bispecific T-cell engagers and chimeric antigen receptors.

Authors:  I Aldoss; R C Bargou; D Nagorsen; G R Friberg; P A Baeuerle; S J Forman
Journal:  Leukemia       Date:  2016-12-28       Impact factor: 11.528

7.  A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo.

Authors:  S Hipp; Y-T Tai; D Blanset; P Deegen; J Wahl; O Thomas; B Rattel; P J Adam; K C Anderson; M Friedrich
Journal:  Leukemia       Date:  2016-12-27       Impact factor: 11.528

Review 8.  Novel immunotherapies in lymphoid malignancies.

Authors:  Connie Lee Batlevi; Eri Matsuki; Renier J Brentjens; Anas Younes
Journal:  Nat Rev Clin Oncol       Date:  2015-11-03       Impact factor: 66.675

Review 9.  Catch me if you can: Leukemia Escape after CD19-Directed T Cell Immunotherapies.

Authors:  Marco Ruella; Marcela V Maus
Journal:  Comput Struct Biotechnol J       Date:  2016-09-28       Impact factor: 7.271

10.  Metastatic colorectal cancer cells from patients previously treated with chemotherapy are sensitive to T-cell killing mediated by CEA/CD3-bispecific T-cell-engaging BiTE antibody.

Authors:  T Osada; D Hsu; S Hammond; A Hobeika; G Devi; T M Clay; H K Lyerly; M A Morse
Journal:  Br J Cancer       Date:  2009-12-01       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.